Fourteen patients (36%) received fedratinib, mainly as second‐line therapy, with a median exposure of 10.5 months (range, 2–22 months), and anemia worsening and concomitant use of erythropoietin were reported in 31% and 33% of cases, respectively. Here, EPO is linked to anemia.